Virtue Insight

PRESENTS

PharmacoVigilance

UK & EU 2026

11 - 12 March 2026

Sheraton Skyline, Heathrow, London, UK

KEY SPEAKERS INCLUDE

#VIphv



KARSTEN LOLLIKE
Scientific VP, Deputy QPPV, Global Patient Safety, Novo Nordisk



MIJAL CHAVDA
Senior Director, Global Head of GxP Inspections & GVP Quality, Kyowa Kirin



CALVIN JOHNSON
Executive Director & Head of International Patient Safety, Bristol-Myers Squibb



STEPHANIE MILLICAN
Deputy Director BRE II
MHRA



REMCO M. DIAB
Sr. Dir. Lead Global Safety Officer Immunology & Inflammation, Sanofi



LEA GALOVIC
Associate Director, Risk Management, Global Patient Safety & PV, Teva



MICHAEL BEAN
Senior Director, Regulatory Compliance
Johnson & Johnson




GYORGY ZORENYI
Senior Medical Director, Medical Safety
Jazz Pharma



YVONNE NANCIU
Country Head Pharmacovigilance Deputy EU QPPV, Bayer



FELIX ARELLANO
Senior VP and Global Head of Safety & Risk Management, Roche



VALENTINA MANCINI
Senior Director Pharmacovigilance, QPPV
Shionogi Europe



TEA BABIC
Director, PV Audits & Inspections
Teva




CHETAN SHATAPATHY
Executive Director & Head, ADC Group, Patient Safety Oncology, AstraZeneca



CHRISTIAN MUHL
Senior Director Compliance
GSK



TERESA SARAGOCA
Director, Regulatory Affairs & Technical Manager, ITALFARMACO



LEONA HOUGHTON
Vice President, Global Safety (Ex-US)
Mundipharma



MARIJA SIMIC
Director Medical Safety Team Lead, Global Patient Safety, Sandoz



SMRUTTI KOTHARI
Associate Director, Global Patient Safety. Quality & Compliance
Regeneron Pharmaceuticals



MIRCEA CIUCA
Independent PV Consultant / International PV Expert (Former Global Head Medical Safety, Organon)



PAV RISHIRAJ
Director, Head of Pharmacovigilance
Ipsen



SABINE POLTERMANN
Head of Country Patient Safety Switzerland
Bristol-Myers Squibb

#VIphv

KEY SPEAKERS INCLUDE



JOHN SOLOMON
Former Head of Pharmacovigilance - UK & Ireland, Sanofi



BEGUM BENLI PEKER
Head of Patient Safety EU Hub
Bristol-Myers Squibb



SIMON ASHWORTH
Head of Pharmacovigilance & Medical Safety, MENARINI Group



SUMIT MUNJAL
Global Head of Medical Safety
Otsuka Pharmaceuticals



RISHI CHOPRA
Head of International PV & Global PV Operations | Dep. UK QPPV, CSL Behring



PHILLIP EICHORN
Global Head of Drug Safety
Amryt Pharma



GALINA CORDERO
Head of Pharmacovigilance Dept, QPPV
JSC Farmak



WOLF HENNING GEBHARDT
R&D Scientist Advanced Analytics
Abbott



ABIDALI FAZAL
Safety Science Director
Roche



MARJAN DZEPAROSKI
Head of Regulatory Affairs, Drug Safety & Intelectual Property
Bionika Pharmaceuticals



RUDI SCHEERLINCK
Safety Strategy Lead – Oncology
Healthcare Business of Merck



MICHAEL VON FORSTNER
Chief Scientific Officer
MedGenie



RAGHDA MOHAMED
Patient Safety Cluster Lead - Middle East & Turkey / Global patient Safety Evaluation
Takeda Pharmaceuticals



GAURI UTTURKAR
Benefit Risk Lead (Associate Director)
UCB



LEONARDO PEREIRA
Clinical Safety Director
Roche



ARUN RAVINDRAN
Benefit Risk Lead (Late phase Clinical Development Safety), UCB



ZINA SADEQ
Director, Regional PV & Alliance Management, UK QPPV
Amicus Therapeutics



CINTHYA GALICIA QUINTANAR
Senior Manager, Country Safety Lead
Pfizer



SANJEEV SRIVASTAV
Signal Management Lead
BioNTech


Plus More Coming Soon...

PLATINUM SPONSOR



#VIphv

KEY THEMES DISCUSSED THIS YEAR



CONFERENCE INTRO

The global pharmacovigilance (PV) market, valued at USD 7.9–10.4 billion in 2024, is expected to reach USD 20–22 billion by 2035, growing at a CAGR of 7–9%. Growth is driven by rising adverse drug reactions (ADRs)—a leading cause of over 100,000 U.S. deaths and 197,000 in Europe annually—stricter regulations, and the complexity of drug pipelines. Global R&D spending exceeds USD 255 billion, with 460,000+ clinical trials underway, fueling demand for advanced PV systems and regulatory compliance initiatives such as RMPs and REMS.

Digital transformation is reshaping PV, with AI, predictive analytics, and automation improving signal detection and reducing safety analysis timelines by 30–50%. Outsourcing remains strong, with 60–70% of major pharma companies leveraging CROs for global PV support. Emerging markets, especially Asia - Pacific, are accelerating growth as clinical trial activity surges. Over the next decade, PV will evolve into a proactive, predictive function central to drug safety and regulatory strategy, supported by real-world evidence (RWE), harmonized regulations, and scalable tech infrastructure.

Governments worldwide are investing heavily in pharmacovigilance to tackle rising ADRs, driving strong market growth. This event unites top pharma, biotech, and regulatory leaders to address key industry challenges. Join us to network with peers, share expertise, and gain insights to elevate your department. Explore the full communications value chain, connect with global vendors, and make the most of dedicated networking sessions.

It gives me great pleasure in welcoming all of you to the Virtue Insight's 40th Pharmacovigilance UK & EU 2026. I wish and pray that all our efforts will be beneficial to our industries and to our all at large.

WHY SHOULD YOU ATTEND

NETWORKING

Curated networking opportunities designed for pharma and biotech professionals to connect at a meaningful, peer level

KNOWLEDGE SHARING

Engage with senior industry leaders sharing strategic perspectives shaping the future of pharma and biotech

SESSION FORMATS

Discussion-driven sessions in a focused, relaxed environment-unlike traditional large-scale exhibitions

NETWORKING APP

Connect with participants 72 hours before and after the event through the Virtue Insight app

WHO SHOULD ATTEND

CEO's, CTO's, CIO's, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

- Pharmacovigilance
- Pharmacoepidemiology
- Pharmacogenomics
- Drug/Product Safety
- Drug Development
- Information and CDM
- Clinical Pharmacology
- Clinical Safety
- Periodical safety update reports
- RMP / REMS
- RWE / RWD
- Research & Development
- Quality Assurance
- Patient Safety
- Signal Detection
- Safety Surveillance
- Outcomes Research
- Data Analysis
- Epidemiology
- Medical Affairs
- Regulatory Affairs and Compliance
- Information Technology
- Sales and Marketing

FOR SPONSORSHIP OPPORTUNITIES

Sponsorship or exhibition is the best way to speed network with decision makers. The world leader speakers in our conferences attract niche delegates from all over the world. This would be a wonderful opportunity to reach the right audience and save money and time on all your other advertising gimmicks. To give you an advertising edge we constantly update the industry pioneers via emails/news letter about the event and advertise the event via different forms of media.

Sponsorship Enquires - sponsor.uk@virtueinsight.com

FOR DELEGATE REGISTRATIONS

Our potent conference agenda delivering the latest information and the world class leaders as speakers attract delegates to attend from around the world. We aim for our attendees to be equipped with knowledge of latest developments & enable them to network with the industry key personnel.

Delegate Registration - delegate.uk@virtueinsight.com

#VIphv

DAY 1 - 11 March 2026

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.

09:15 – Opening Remarks / Welcome Address

09:30 – Chairperson opening remarks

PAV RISHIRAJ
Director, Head of Pharmacovigilance
Ipsen

BEYOND COMPLIANCE

09:40 – Beyond compliance: How we can do more for patients in PV

Patient voices in PV are still underutilized. We can move beyond compliance and do our best to make safety truly patient-centered.

This presentation will cover the current state, why it matters to include patient voices and how we can do more and move from "checking the box" to doing our best for patients.

BEGUM BENLI PEKER
Head of Patient Safety EU Hub
Bristol-Myers Squibb

SAFETY

10:20 – Safety monitoring in clinical studies

- Proactive monitoring
- Timely detection and management of safety issues
- Interaction & communication with stakeholders.

RUDI SCHEERLINCK
Safety Strategy Lead – Oncology
Healthcare Business of Merck

10:50 – Morning Coffee/Tea & Networking

11:20 – Topic TBC

Speaker TBC
ArisGlobal

LATEST UPDATES & HOT TOPICS

11:50 – Keynote Panel Discussion: Pharmacovigilance: Innovations, Challenges & Global Best Practices - Best practices & the way forward

Moderator

RUDI SCHEERLINCK
Safety Strategy Lead – Oncology
Healthcare Business of Merck

Panellists

REMCO M. DIAB
Sr. Dir. Lead Global Safety Officer Immunology & Inflammation, Sanofi

VALENTINA MANCINI
Senior Director Pharmacovigilance, QPPV
Shionogi Europe

MARIJA SIMIC
Director Medical Safety Team Lead, Global Patient Safety
Sandoz

LEONARDO PEREIRA
Clinical Safety Director
Roche

SUMIT MUNJAL
Global Head of Medical Safety
Otsuka Pharmaceuticals

SIMON ASHWORTH
Head of Pharmacovigilance & Medical Safety
MENARINI Group

12:50 – Networking luncheon

PATIENT CENTRIC PV

13:50 – Panel Discussion – Patient-Centric PV: Elevating Drug Safety through Engagement. Making drug safety monitoring more proactive, data-driven, and human-centered

Moderator

YVONNE NANCIU
Country Head Pharmacovigilance Deputy EU QPPV
Bayer

Panellists

ABIDALI FAZAL
Safety Science Director
Roche

RISHI CHOPRA
Head of International PV & Global PV Operations | Dep. UK QPPV, CSL Behring

MICHAEL VON FORSTNER
Chief Scientific Officer
MedGenie

CINTHYA GALICIA QUINTANAR
Senior Manager, Country Safety Lead
Pfizer

MEDICAL DEVICES

14:50 – Medical Device Vigilance: Important Considerations to Comply With the EU MDR

- Medical Device Vigilance vs Pharmacovigilance
- Causality Assessment
- Clinical Reporting & Postmarketing Reporting Requirements
- Reporting Formats

15:10 - Afternoon Tea/Coffee

MARKET TRENDS & WAY AHEAD

15:40 – Future of pharmacovigilance - Making medicines safe in an increasingly complex world

- Pharmacovigilance: What comes next for the industry?
- Transforming the science at the heart of pharmacovigilance
- Building trust and openness with technology
- Automating to innovate
- Does the shift towards emerging markets pose a risk to drug safety and biased data reports?

RAGHDA MOHAMED
Patient Safety Cluster Lead - Middle East & Turkey / Global patient Safety Evaluation, Takeda Pharmaceuticals

OUTSOURCING

16:10 - Panel Discussion – The Evolving Era of PV Outsourcing: Recent Developments, Innovations and Best Practices

Moderator

PAV RISHIRAJ
Director, Head of Pharmacovigilance
Ipsen

Panellists

GYORGY ZORENYI
Senior Medical Director, Medical Safety
Jazz Pharma

LEONA HOUGHTON
Vice President, Global Safety (Ex-US)
Mundipharma

ZINA SADEQ
Director, Regional PV & Alliance Management, UK QPPV
Amicus Therapeutics

PHILLIP EICHORN
Global Head of Drug Safety
Amryt Pharma

17:00 - Chairperson's closing remarks and end of conference

17:10 – 18:10 - Networking Drinks Session

DAY 2 - 12 March 2026

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.

09:00 – Chairperson opening remarks

PAV RISHIRAJ
Director, Head of Pharmacovigilance
Ipsen

PV FOR FUTURE

09:10 – Beyond the Algorithm – The Human-AI Partnership in Pharmacovigilance

- Examines common anxieties about AI replacing human roles in pharmacovigilance and reframes these concerns to highlight new opportunities.
- Demonstrates how rekindling childlike curiosity and creativity in adult professionals can happen.
- Discusses practical approaches for building transparent, accountable processes when integrating AI into safety practices.
- Emphasizes the irreplaceable value of human judgement, empathy, and imagination alongside evolving AI technologies.

SABINE POLTERMANN
Head of Country Patient Safety Switzerland
Bristol-Myers Squibb

RWD / RWE

09:40 – Panel Discussion: Harnessing RWD & RWE: Transforming the Future of Pharmacovigilance

Moderator

SANJEEV SRIVASTAV
Signal Management Lead
BioNTech

Panellists

WOLF HENNING GEBHARDT
R&D Scientist Advanced Analytics
Abbott

RAGHDA MOHAMED
Patient Safety Cluster Lead - Middle East & Turkey / Global patient Safety Evaluation
Takeda Pharmaceuticals

10:20 - Solution Provider Presentation

For sponsorship opportunities please contact
info.uk@virtueinsight.com

10:40 – Morning Coffee/Tea & Discussion

RISK MANAGEMENT & PLANNING

11:10 – Keynote Panel Discussion: Benefit-Risk Excellence: Innovative Approaches to Risk Management

Moderator

MIRCEA CIUCA
Independent PV Consultant / International PV Expert (Former Global Head Medical Safety, Organon)

Panellists

FELIX ARELLANO
Senior VP and Global Head of Safety & Risk Management
Roche

CHETAN SHATAPATHY
Executive Director & Head, ADC Group, Patient Safety Oncology, AstraZeneca

GAURI UTTURKAR
Benefit Risk Lead (Associate Director)
UCB

LEA GALOVIC
Associate Director, Risk Management, Global Patient Safety & PV, Teva

JOHN SOLOMON
Former Head of Pharmacovigilance - UK & Ireland
Sanofi

ARUN RAVINDRAN
Benefit Risk Lead (Late phase Clinical Development Safety), UCB

12:00 – Solution Provider Presentation

For sponsorship opportunities please contact info.uk@virtueinsight.com

12:30 – Networking luncheon

AUDITS & INSPECTIONS

13:30 – Panel Discussion - Plan, Develop & Implement the PV Audit strategy plan. PV Inspection readiness: What to expect? How ready can we be?

Moderator

MIJAL CHAVDA
Senior Director, Global Head of GxP Inspections & GVP Quality, Kyowa Kirin

Panellists

KARSTEN LOLLIKE
Scientific VP, Deputy QPPV, Global Patient Safety
Novo Nordisk

TEA BABIC
Director, PV Audits & Inspections
Teva

CHRISTIAN MUHL
Senior Director Compliance
GSK

SMRUTTI KOTHARI
Associate Director, Global Patient Safety. Quality & Compliance, Regeneron Pharmaceuticals

GALINA CORDERO
Head of Pharmacovigilance Dept, QPPV
JSC Farmak

REGULATORY

14:20 - Harmonizing Local PV Activity to Improve Efficiency" with the accent on non_EU Countries (Balkan).

MARJAN DZEPAROSKI
Head of Regulatory Affairs, Drug Safety & Intelectual Property, Bionika Pharmaceuticals

14:40 – Panel Discussion: Regulatory Synergy in PV: Challenges, Opportunities & the Road Ahead

Moderator

PAV RISHIRAJ
Director, Head of Pharmacovigilance
Ipsen

Panellists

STEPHANIE MILLICAN
Deputy Director BRE II
MHRA

MICHAEL BEAN
Senior Director, Regulatory Compliance
Johnson & Johnson

CALVIN JOHNSON
Executive Director & Head of International Patient Safety
Bristol-Myers Squibb

TERESA SARAGOCA
Director, Regulatory Affairs & Technical Manager
ITALFARMACO

15:30 - Chairperson's closing remarks

15:40 – Evening Tea/Coffee and end of the conference

REGISTER ONLINE :

Link : https://virtueinsight.com/events/pharmacovigilance-uk-eu-2026/

For Multiple Bookings - Photocopy this form and send it to info.uk@virtueinsight.com

Delegate Details:

Title Mr ☐ Mrs ☐ Ms ☐ Dr ☐

First Name

Surname

Company

Position

Address

Pincode

Telephone

Fax

Email

RESERVATION PRICING

SUPER EARLY BIRD PRICE (Valid until 11 December 2025)

1 Delegate @ **£ 799 + VAT**

Group Discount @ **£ 1598 + VAT** (3 Delegates for the price of 2)

STANDARD PRICE

1 Delegate @ **£ 1299 + VAT**

Group Discount @ **£ 2598 + VAT** (3 Delegates for the price of 2)

CERTIFICATION

E-Certificate of attendance would be provided to attendees on request, upon completion of conference

Payment option (Choose one of the following payment options)

Please send me a VAT invoice ☐

I enclose a cheque for $

Please charge my card $

Card Number ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Security No ☐☐☐

Expiry Date ☐☐☐☐

Cardholder's Name

Cardholder's Registered Address

Signature

Our purchase order no.is

Payable to Virtue Insight Events Ltd

Card type: Visa ☐ Mastercard ☐ Maestro ☐ Amex ☐

FOR BANK TRANSFER:

Account Name - Virtue Insight Events Ltd
Account Number - 53278603
Bank Name - Barclays Bank PLC **Sort Code** - 20-84-20
SWIFT Code: BARCGB22 **IBAN Code**: GB36BARC20842053278603
ROUTING Code: 026002574

#VIphv

General Information Venue:

Sheraton Skyline Hotel London Heathrow
Heathrow Airport, Sheraton Heathrow, A4 Bath Rd, Harlington, Hayes UB3 5BP, United Kingdom, Tel: +44 20 8759 2535

TERMS AND CONDITIONS:

Payment terms: Virtue Insight requires the full amount to be paid before the conference. We may refuse entry to delegates who have not paid their invoice in full.

Cancellations: Delegates and vendors are subject to the following charges and refunds upon withdrawal or cancellation between 2-3 month's prior 75% cancellation fee/ 25% refund. Less than 2 months prior to the event Full cancellation fee / No refund.

Administration Fee: If you cancel your participation (once confirmed) and haven't paid the attendance fee you will be liable to pay an administration fee of £200

Substitutions/Name Change: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. This can be done at no extra cost.

Presentation: If you cannot attend the conference, you can still purchase the presentations (Subject to availability) - Please email to bookings@virtueinsight.com

Indemnity: Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will reschedule the event.

Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hotel accommodation.

Payment Charges: We are a UK registered company and use Barclaycard payment gateway. Some card providers do charge a small foreign transaction fees for international payment (this is not charged from our end). If not sure please contact your card provider before making payment.

Covid Situation, Natural Calamity, National Security: In the case where the government decide to go into a lockdown or restrictions on social and business gatherings during the dates of the conference, the event will be postponed to a new date. Registered clients can choose to join the conference on the new date or decide to take a credit note for their payment so that they can decide to participate for any of our future events within the time frame of next one year.